February 15, 2018 / 7:44 AM / in 8 months

BRIEF-Neurovive Decides On A Rights Issue For Continued Drug Development

Feb 15 (Reuters) - NEUROVIVE PHARMACEUTICAL AB:

* NEUROVIVE DECIDES ON A RIGHTS ISSUE FOR CONTINUED DRUG DEVELOPMENT

* ‍TO ISSUE SHARES AND WARRANTS WITH PREFERENTIAL RIGHTS FOR EXISTING SHAREHOLDERS (“RIGHTS ISSUE”)​

* ‍UPON FULL SUBSCRIPTION TO RIGHTS ISSUE, CO WILL RECEIVE ABOUT MSEK 78.5 BEFORE ISSUANCE COSTS.​

* ‍IN FULL EXERCISE OF WARRANTS ISSUED IN RIGHTS ISSUE, CO WILL RECEIVE AN ADDITIONAL MSEK 37.3 BEFORE ISSUANCE COSTS.​

* ‍SUBSCRIPTION PRICE IS SEK 8 PER UNIT, CORRESPONDING TO SEK 2 PER SHARE.​

* ‍SUBSCRIPTION PERIOD RUNS FROM 10 APRIL - 24 APRIL 2018.​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below